Abstract
Background Respiratory diseases such as chronic obstructive pulmonary disease (COPD) have been associated with increased risk of severe SARS-CoV-2 infection, but the mechanisms and putative immune pathways are unclear. Besides, increased levels of several immune mediators in patients with severe coronavirus disease 19 (COVID-19) have been reported.
Objective To perform an immunoproteomic profiling of dysregulated plasma proteins in patients with asthma and COPD and to evaluate their relationship with biomarkers of severe COVID-19.
Methods 92 protein biomarkers were quantified in 315 plasma samples from adult subjects (age 40-90 years) including 118 asthmatics, 99 COPD patients and 98 healthy controls, that have been recruited in two reference pneumology clinics in Colombia before the beginning of the COVID-19 pandemic.
Results Forty-one plasma proteins showed differences between patients and controls. Asthmatic patients have increased levels in IL-6 and CCL3 while COPD patients have a broader systemic inflammatory dysregulation driven by HGF, OPG, and several chemokines (CXCL9, CXCL10, CXCL11, CX3CL1, CXCL1, MCP-3, MCP-4, CCL3, CCL4 and CCL11). Functional annotation revealed their enrichment in chemokine signaling pathways related with response to viral infections. Some of these proteins were found up-regulated upon SARS-Cov-2 infection of Calu-3 cells. Also, HPG, CXCL9, CXCL10, IL-6, MCP-3, TNF and EN-RAGE have been found increased in patients with severe COVID-19. HGF, the most significant protein in this study as well as its correlated proteins could be associated with the increased risk of severe COVID-19 in COPD patients.
Conclusions Asthma and COPD patients have altered plasma levels of proteins that have been found associated with increased risk of severe COVID-19. The reasons for sharing these profiles with this infection are unknown, but our study suggest that adult patients with asthma and COPD have a systemic dysregulation in chemokine networks that could make them more susceptible to severe COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was financed by the Ministry of Science (Republic of Colombia, Grant 756-2017) and the University of Cartagena
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The plasma samples were obtained from the Identification of Biomarkers in Asthma and COPD cohort (IBACO), aimed to identify biomarkers of chronic respiratory diseases in Colombia. Patients were recruited from two reference pneumology clinics of Cartagena and Bogota. The study was approved by the ethical committees of the University of Cartagena (nr. 4169722017) and the Fundacion Neumologica Colombiana (nr. 232-07122017) and written informed consent was obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data regarding this manuscript is available from the corresponding author on request
Abbreviations
- CCL3
- C-C motif chemokine ligand 3 or Macrophage inflammatory protein 1-alpha
- CCL4
- C-C motif chemokine ligand 4 or Macrophage inflammatory protein 1-beta
- CCL11
- C-C Motif chemokine ligand 11 or eotaxin-1
- COPD
- Chronic obstructive pulmonary disease
- COVID-19
- Coronavirus disease 19
- CSF-1
- Colony stimulating factor 1
- CST5
- Cystatin-D
- CX3CL1
- C-X3-C motif chemokine ligand 1 (fractalkine)
- CXCL1
- C-X-C motif chemokine ligand 1 or Neutrophil-activating protein 3
- CXCL5
- C-X-C motif chemokine ligand 5 or Neutrophil-activating protein 78
- CXCL9
- C-X-C motif chemokine ligand 9 or Monokine induced by interferon-gamma
- CXCL10
- C-X-C motif chemokine ligand 10 or IP-10
- CXCL11
- C-X-C motif chemokine ligand 11 or interferon-inducible T-cell alpha chemoattractant
- EN-RAGE
- extracellular newly identified receptor for advanced glycation end-products binding protein or S100 Calcium Binding Protein A12
- HGF
- Hepatocyte Growth Factor or lung fibroblast-derived mitogen
- IL10RB
- Interleukin 10 receptor subunit beta
- KEGG
- Kyoto Encyclopedia of Genes and Genomes
- MCP-3
- Monocyte chemoattractant protein 3 or CCL7
- MCP-4
- Monocyte chemotactic protein 4 or CCL13
- MMP-1
- Matrix metallopeptidase 1
- OPG
- Osteoprotegerin or Tumor necrosis factor receptor superfamily, member 11b
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2
- SLAF1
- Signaling lymphocytic activation molecule family member 1
- ST1A1
- Sulfotransferase family 1A member 1
- TMPRSS2
- Transmembrane serine protease 2
- TNF
- Tumor Necrosis Factor
- TNFRSF9
- TNF receptor superfamily member 9
- TNFSF14
- TNF superfamily member 14
- TRANCE
- TNF superfamily member 11 or Receptor activator of Nuclear Factor Kappa B Ligand
- VEGFA
- Vascular Endothelial Growth Factor A
